Clinuvel Pharmaceuticals vs Recursion Pharmaceuticals
Recursion Pharmaceuticals is the larger business, with $74.7m of revenue in fiscal 2025 against $64.3m for Clinuvel Pharmaceuticals (1.2 times as much). Recursion Pharmaceuticals grew faster (26.9% against 5.2%). Clinuvel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 36.0% against -863.4%. Clinuvel Pharmaceuticals carries less debt relative to equity (0.0% against 1.6%).
| Latest fiscal year | Clinuvel PharmaceuticalsCUVL, 2026 | Recursion PharmaceuticalsRXRX, 2025 |
|---|---|---|
| Revenue | $64.3m | $74.7m |
| Revenue growth | 5.2% | 26.9% |
| Net income | $23.2m | −$645m |
| Operating margin | 43.4% | -867.9% |
| Net margin | 36.0% | -863.4% |
| Return on equity | 13.4% | -59.5% |
| Free cash flow | $11.8m | −$378m |
| Cash | $13.9m | $743m |
| Total debt | $0 | $18.7m |
| Debt to equity | 0.0% | 1.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $256m | $2.10bn |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 35 sales |